Article Information
History
- April 20, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Mie Agermose Gram1,*,
- Hanne-Dorthe Emborg1,
- Astrid Blicher Schelde1,
- Nikolaj Ulrik Friis1,
- Katrine Finderup Nielsen1,
- Ida Rask Moustsen-Helms1,
- Rebecca Legarth2,
- Janni Uyen Hoa Lam2,
- Manon Chaine2,
- Aisha Zahoor Malik2,
- Morten Rasmussen3,
- Jannik Fonager3,
- Raphael Niklaus Sieber4,
- Marc Stegger4,
- Steen Ethelberg1,5,
- Palle Valentiner-Branth1 and
- Christian Holm Hansen1
- 1Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark
- 2Division of Infectious Disease Preparedness, Data Integration and Analysis, Statens Serum Institut, Copenhagen, Denmark
- 3Department of Virus Research and Development Laboratory, Virus and Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark
- 4Department of Bacteria, Parasites, and Fungi, Statens Serum Institut, Copenhagen, Denmark
- 5Department of Public Health, Global Health Section, University of Copenhagen, Copenhagen, Denmark
- ↵*Corresponding author MIAG{at}ssi.dk (MIAG)
Posted April 20, 2022.
Vaccine effectiveness against SARS-CoV-2 infection and COVID-19-related hospitalization with the Alpha, Delta and Omicron SARS-CoV-2 variants: a nationwide Danish cohort study
